Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048186 · ClinicalTrials.gov registry record
Refining the Shared Decision Making Process Survey in ADHD Medication Decisions
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 512
- Enrollment target
NCT05048186: Completed study, sponsored by Massachusetts General Hospital.
NCT05048186 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 512 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05048186 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 512 participants
- Enrollment target
Study Summary
This is a retrospective observational survey study. We will survey a sample of adult parents or legal guardians who have a child who has been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) and who discussed ADHD treatment options for their child with a health care provider within the last 2 years. The main goal is to gather evidence of the validity and reliability of the Shared Decision Making Process scale. Secondary goal is to gather evidence on the quality of decisions parents make about their children with ADHD. A third goal is to assess the impact of a Decision Aid on participant knowledge of ADHD treatment options. Participants will be randomized to one of two arms: participants in the intervention arm will review a Decision Aid (patient educational tool) partway through the survey and those in the control arm will not receive any educational materials. All participants will complete survey that includes the Shared Decision Making process survey along with a few other measures. A subset of respondents will also complete a retest survey about two weeks after the initial survey.
Primary Outcome
The Shared Decision Making Process scale is a short patient-reported survey that measures the amount of shared decision making that occurs in an interaction. Scores range from 0-4 where higher values indicate a better shared decision making process occurred.
Interventions
- BEHAVIORAL Attention Deficit Hyperactivity Disorder Treatment Decision Aid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2021-04-13 |
What the finished NCT05048186 record still lists
NCT05048186 is an observational study that tracks outcomes without assigning an intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Attention Deficit Hyperactivity Disorder Treatment Decision Aid is the first listed.
NCT05048186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05048186 about?
NCT05048186 is a clinical study titled "Refining the Shared Decision Making Process Survey in ADHD Medication Decisions". This is a retrospective observational survey study. We will survey a sample of adult parents or legal guardians who have a child who has been diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) and who discussed ADHD treatment options for their child with a health care provider within the...
What is the current status of trial NCT05048186?
This trial is currently completed. The enrollment target is 512 participants. The study started on 2021-02-24. Estimated completion is 2021-04-13.
What interventions are being tested in trial NCT05048186?
The interventions under investigation include: Attention Deficit Hyperactivity Disorder Treatment Decision Aid (BEHAVIORAL).
Who is sponsoring clinical trial NCT05048186?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI